ID   CUTO-18
AC   CVCL_C8TH
SY   CUTO18; Colorado University Thoracic Oncology 18
DR   Wikidata; Q123030988
RX   PubMed=33355298;
CC   Sequence variation: Mutation; HGNC; HGNC:3236; EGFR; Simple; p.Ser768_Asp770dupSerValAsp (c.2303_2311dup) (S768_D770dupSVD); ClinVar=VCV000045253; Zygosity=Heterozygous (PubMed=33355298).
DI   NCIt; C3512; Lung adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
CA   Cancer cell line
DT   Created: 05-10-23; Last updated: 19-12-24; Version: 3
//
RX   PubMed=33355298; DOI=10.1158/1078-0432.CCR-20-3555; PMCID=PMC7926264;
RA   Estrada-Bernal A., Le A.T., Doak A.E., Tirunagaru V.G., Silva S.,
RA   Bull M.R., Smaill J.B., Patterson A.V., Kim C., Liu S.V.,
RA   Doebele R.C.;
RT   "Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active
RT   against a broad range of HER-family oncogenes.";
RL   Clin. Cancer Res. 27:1463-1475(2021).
//